BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31206982)

  • 21. Novel therapeutic approaches to the treatment of Wilson's disease.
    Brewer GJ
    Expert Opin Pharmacother; 2006 Feb; 7(3):317-24. PubMed ID: 16448326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wilson's disease.
    Ala A; Walker AP; Ashkan K; Dooley JS; Schilsky ML
    Lancet; 2007 Feb; 369(9559):397-408. PubMed ID: 17276780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
    Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trientine-induced neurological deterioration in a patient with Wilson's disease.
    Kim B; Chung SJ; Shin HW
    J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease.
    Wiggelinkhuizen M; Tilanus ME; Bollen CW; Houwen RH
    Aliment Pharmacol Ther; 2009 May; 29(9):947-58. PubMed ID: 19210288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurological worsening in Wilson disease - clinical classification and outcome.
    Mohr I; Pfeiffenberger J; Eker E; Merle U; Poujois A; Ala A; Weiss KH
    J Hepatol; 2023 Aug; 79(2):321-328. PubMed ID: 37116715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical considerations for an effective medical therapy in Wilson's disease.
    Weiss KH; Stremmel W
    Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
    Brewer GJ
    CNS Drugs; 2005; 19(3):185-92. PubMed ID: 15740174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penicillamine-induced Elastosis Perforans Serpiginosa in Wilson Disease: Is Useful Switching to Zinc?
    Ranucci G; Di Dato F; Leone F; Vajro P; Spagnuolo MI; Iorio R
    J Pediatr Gastroenterol Nutr; 2017 Mar; 64(3):e72-e73. PubMed ID: 25341025
    [No Abstract]   [Full Text] [Related]  

  • 32. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
    Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
    Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Wilson disease in 2003].
    Szalay F
    Orv Hetil; 2003 Dec; 144(50):2451-8. PubMed ID: 15067983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse following withdrawal of D-penicillamine from combination (D-penicillamine + zinc) therapy in hepatic Wilson disease.
    Panda K; Lal BB; Sood V; Khanna R; Alam S
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1017-1026. PubMed ID: 38695602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Wilson's disease and its pharmacological treatment].
    Hayashi H; Suzuki R; Wakusawa S
    Yakugaku Zasshi; 2004 Nov; 124(11):711-24. PubMed ID: 15516801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A study of trientine therapy in Wilson's disease with neurological symptoms].
    Suda M; Kubota J; Yamaguchi Y; Fujioka Y; Saito Y; Aoki T
    No To Hattatsu; 1993 Sep; 25(5):429-34. PubMed ID: 8398232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report.
    Tovaru S; Parlatescu I; Dumitriu AS; Bucur A; Kaplan I
    J Periodontol; 2010 Aug; 81(8):1231-6. PubMed ID: 20384464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zinc treatment for symptomatic Wilson disease: moving forward by looking back.
    Schilsky M
    Hepatology; 2009 Nov; 50(5):1341-3. PubMed ID: 19877301
    [No Abstract]   [Full Text] [Related]  

  • 39. Wilson's disease: clinical, genetic and pharmacological findings.
    Leggio L; Addolorato G; Abenavoli L; Gasbarrini G
    Int J Immunopathol Pharmacol; 2005; 18(1):7-14. PubMed ID: 15698506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recognition, diagnosis, and management of Wilson's disease.
    Brewer GJ
    Proc Soc Exp Biol Med; 2000 Jan; 223(1):39-46. PubMed ID: 10632959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.